- Ticker
- ACTI.ST
- Price
- 0.94
- Stock movement down
- -0.01 (-1.26%)
- Company name
- Active Biotech AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 248.20M
- Ent værdi
- 209.60M
- Pris/omsætning
- -
- Pris/bog
- 5.04
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- -13.47%
- 3 års afkast
- -28.72%
- 5 års afkast
- -17.10%
- 10 års afkast
- -29.73%
Senest opdateret: 2023-01-28
UDBYTTE
ACTI.ST betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | - |
| Pris til egenkapital | 5.04 |
| EV i forhold til salg | - |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 264.89M |
| EPS (TTM) | -0.26 |
| FCF pr. aktie (TTM) | -0.25 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 0.00 |
| Bruttofortjeneste (TTM) | 0.00 |
| Driftsindkomst (TTM) | -57.60M |
| Nettoindkomst (TTM) | -58.30M |
| EPS (TTM) | -0.26 |
| EPS (1 år frem) | - |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | - |
| Driftsmargin (TTM) | - |
| Fortjenstmargin (TTM) | - |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 55.00M |
| Nettotilgodehavender | 3.80M |
| Omsætningsaktiver i alt | 58.80M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 65.60M |
| Kreditor | 0.00 |
| Kortfristet/nuværende langsigtet gæld | 0.00 |
| Summen af kortfristede forpligtelser | 12.00M |
| Sum gæld | 16.40M |
| Aktionærernes egenkapital | 49.20M |
| Materielle nettoaktiver | 49.00M |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -56.87M |
| Investeringsudgifter (TTM) | 400.00K |
| Fri pengestrøm (TTM) | -57.27M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -118.50% |
| Afkast af aktiver | -88.87% |
| Afkast af investeret kapital | -118.50% |
| Kontant afkast af investeret kapital | -116.39% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 0.95 |
| Daglig høj | 0.95 |
| Daglig lav | 0.92 |
| Daglig volumen | 57K |
| Højeste gennem alle tider | 321.94 |
| 1 års analytiker estimat | 2.80 |
| Beta | 0.54 |
| EPS (TTM) | -0.26 |
| Udbytte pr. aktie | - |
| Ex-div dato | 17 Apr 1998 |
| Næste dato for resultatpræsentation | 9 Feb 2023 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ACTI.ST | S&P500 | |
| Nuværende prisfald fra top notering | -99.71% | -15.08% |
| Højeste prisfald | -99.73% | -56.47% |
| Højeste efterår dato | 13 Oct 2022 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -91.41% | -11.49% |
| Gennemsnitlig tid til nyt højdepunkt | 6526 days | 13 days |
| Maks. tid til nyt højdepunkt | 6525 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
248.20M
Markedsværdi kategori
Small-cap
Beskrivelse
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Personale
9
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Sweden
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab...
1. juni 2022
The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical att...
19. maj 2022
Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of mye...
18. maj 2022
Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active Biotech AB...
28. april 2022
Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech’s patent related to use of laquinimod ...
26. april 2022
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07)Active ...
21. april 2022
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Thursday, May 19, 2022. Due to the situation resulting from the Corona virus, the M...
20. april 2022
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company’s incentive program for the company’s employees (Plan 2020/2024). Today, t...
31. marts 2022
The correction refers to the administrative costs for the period January – December 2021 that due to oversight have been stated too low. The incorrect amount was SEK 14,0 M, the correct amount is SEK ...
25. marts 2022
FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular pr...
9. februar 2022
Næste side